

AMENDMENT

In The Claims

14. (currently amended) A cytomodulating conjugate for administration to a mammalian host, said conjugate consisting essentially of folate joined to a selective moiety, wherein said selective moiety is other than an antibody or fragment thereof and consists essentially of an antigen to which the host has been previously sensitized or to which the host has natural immunity.

15. (original) The conjugate of Claim 14, wherein said selective moiety is selected from the group consisting of a blood group antigen, a xenoantigen, and at least a portion of a vaccine antigen.

16. (original) The conjugate of Claim 14, wherein said selective moiety binds to anti- α -gal antibodies.

17. (original) The conjugate of Claim 16, wherein said selective moiety is the α -galactosyl epitope.

18. (withdrawn) The conjugate of Claim 14, wherein said selective moiety comprises an antigen selected from the group consisting of an oligosaccharide A antigen, an oligosaccharide B antigen, a vaccine antigen, and fluorescein isothiocyanate (FITC).

19. (currently amended) A cytomodulating conjugate consisting essentially of folate joined to a selective moiety, wherein said selective moiety is other than an antibody or fragment thereof and consists essentially of an epitope selected from the group consisting of Gal α 1-3 Gal β 1-4 GlcNAc-R α -galactosyl, a blood group antigen, a xenoantigen, HIV, a vaccine antigen, a minor histocompatibility antigen, and fluorescein isothiocyanate (FITC).

20. (currently amended) A conjugate consisting essentially of folate covalently joined to Gal α 1-3 Gal β 1-4 GlcNAc-R fluorescein isothiocyanate (FITC).

21. (withdrawn) The conjugate of Claim 14 wherein said selective moiety consists essentially of fluorescein isothiocyanate (FITC).

22. (withdrawn) The conjugate of Claim 19 wherein said selective moiety consists essentially of fluorescein isothiocyanate (FITC).